[Form 4] Royalty Pharma plc Insider Trading Activity

Rhea-AI Filing Summary

Royalty Pharma plc executive Marshall Urist, EVP of Research & Investments, reported selling 20,000 Class A Ordinary Shares on December 16, 2025. The sale, coded as "S," was executed at a weighted average price of $38.321 per share, with individual trades ranging from $38.24 to $38.40. All transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 16, 2025.

Following this activity, Urist reports beneficial ownership of 140,000 Class A shares indirectly through Sandy Lamm LLC, 19,020 shares indirectly through an IRA, and 7,398 shares held directly. In addition, Urist and related family vehicles hold limited partnership interests exchangeable into 2,474,120 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into a further 1,356,528 Class A Ordinary Shares, with the Class E shares subject to vesting conditions.

Insider Trade Summary

Net Seller: 20,000 shares ($766,420)

Net Sell 3 txns

Insider Urist Marshall

Role EVP, Research & Investments

Sold 20,000 shs ($766K)

Type	Security	Shares	Price	Value
Sale	Class A Ordinary Shares	20,000	$38.321	$766K
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--

Holdings After Transaction: Class A Ordinary Shares — 140,000 shares (Indirect, By Sandy Lamm LLC); Class A Ordinary Shares — 7,398 shares (Direct)

Footnotes (1)

1. All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on September 16, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.24 to $38.40 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Urist Marshall

(Last) (First) (Middle)

C/O ROYALTY PHARMA PLC

110 EAST 59TH STREET

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Research & Investments

3. Date of Earliest Transaction (Month/Day/Year)
12/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Shares	12/16/2025		S(1)		20,000	D	$38.321(2)	140,000	I	By Sandy Lamm LLC
Class A Ordinary Shares								19,020	I	By IRA
Class A Ordinary Shares								7,398	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on September 16, 2025.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.24 to $38.40 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

In addition to the Class A Ordinary Shares disclosed above, the Reporting Person and family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 2,474,120 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd ("RPH") exchangeable into 1,356,528 Class A Ordinary Shares. Class E Ordinary Shares of RPH are subject to vesting conditions.

	/s/ Sean Weisberg, as Attorney-in-Fact, for Marshall Urist	12/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Royalty Pharma (RPRX) report for Marshall Urist?

Marshall Urist, EVP of Research & Investments at Royalty Pharma plc, reported the sale of 20,000 Class A Ordinary Shares on December 16, 2025, coded as a sale transaction.

At what price were the 20,000 Royalty Pharma (RPRX) shares sold by Marshall Urist?

The 20,000 Class A shares were sold at a weighted average price of $38.321 per share. The trades occurred in multiple transactions at prices ranging from $38.24 to $38.40 per share.

Was the Royalty Pharma (RPRX) insider sale by Marshall Urist under a 10b5-1 plan?

Yes. The filing states that all reported transactions were effected under a Rule 10b5-1 trading plan adopted by Marshall Urist on September 16, 2025.

How many Royalty Pharma (RPRX) shares does Marshall Urist report owning after the sale?

After the reported sale, Marshall Urist reports 140,000 Class A shares indirectly through Sandy Lamm LLC, 19,020 shares indirectly through an IRA, and 7,398 shares held directly.

What additional exchangeable interests related to Royalty Pharma (RPRX) does Marshall Urist hold?

The filing notes that Urist and family vehicles hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 2,474,120 Class A Ordinary Shares, and Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into 1,356,528 Class A Ordinary Shares, with the Class E shares subject to vesting conditions.

What is Marshall Urist's role at Royalty Pharma (RPRX)?

Marshall Urist is identified as an officer of Royalty Pharma plc, serving as EVP, Research & Investments, and is the reporting person for this insider transaction.